Zakazenia fenotypem Van B Enterococcus faecium i E.faecalis u chorych z niedoborem immunologicznym w przebiegu chorob nowotworowych ukladu krwiotworczego

• Autorzy: Kedzierska J. , Wegrzyn J. , Skotnicki A.B. , Skop A. , Pawliszyn W.
• Języki publikacji: PL

Abstrakty

PL

W pracy przeanalizowano drugą, udokumentowaną w Polsce epidemię VRE wywołaną fenotypem VanB. Uzyskano jeden izolat VREM oporny na teikoplaninę od chorego będącego w trakcie terapii tym antybiotykiem. Potwierdzono zależność pomiędzy wcześniejszym stosowaniem wankomycy- ny, cefalosporyn i imipenemu a częstością występowania zakażeń i kolonizacji VRE. Odnotowano znaczący udział analizowanych szczepów VRES i VREM jako czynników przyczynowych jednorodnych etiologicznie zakażeń uogólnionych w badanej grupie chorych.

EN

In this work, we have analyzed the second outbreak of VRE with the VanB phenotype to be identified in the country. The aim of this study was to characteristics of the types of resistance to glycopeptide antibiotic and to check the resistance patterns of these pathogens. A trial of monitoring the risk factors for colonization or infection with VRE as well as epidemiological investigation were undertaken. Genus identification of the isolates was performed according to the method of Facklam and Collins, and species were identified using the API 20 Strep test. MICS of different antimicrobial agents were determined by the E-test method. The isolates collected during the investigation demonstrated resistance to multiple antimicrobials, which is a common characteristic of VRE. Isolates were found to be uniformly resistant to penicillin, fluoroquinolones, tetracycline and to high concentrations of aminoglycosides. The only drugs with in vitro activity against the isolates were ampicillin (VRES), linezolid (VRES,VREM) and quinupristin-dalfopristin (VREM). Except for a single VREM isolate, they all revealed the typical VanB phenotype with resistance to vancomycin and susceptibility to teicoplanin. One of the VREM isolates turned out to be resistant to teicoplanin, which coincided with the use of this antibiotic in the patient's therapy. Its vanB gene variant differed by a single mutation from that found in other isolates; however, it also lacked a large part of the vanB gene claster, including the regulatory genes vanRв and -Sb, and the vancomycin - inducible promoter Pyb- Our studies have found an association between colonization or infection with VRE and the mean duration of hospital stay, previously administration of glycopeptide, cephalosporins and imipenem. These organisms were a common cause of monoetiological bloodstream infections.

Słowa kluczowe

PL

Enterococcus faecalis; ziarenkowce; nowotwory; choroby czlowieka; Enterococcus faecium; enterokoki; immunologia; uklad krwionosny; zakazenia szpitalne

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2003
• Tom: 55
• Numer: 1
• Opis fizyczny: s.11-24,tab.,bibliogr.

Twórcy

autor

Kedzierska J.

• Szpital Uniwersytecki, Krakow

autor

Wegrzyn J.

autor

Skotnicki A.B.

autor

Skop A.

autor

Pawliszyn W.

Bibliografia

• 1. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993; 37: 1563-71.
• 2. Aslangul E, Baptista M, Fantin F i inni. Selection of glycopeptide-resistant mutants of vanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis. J Infect Dis 1997; 175: 598-605.
• 3. Baptista M, Rodrigues P, Depardieu P. i inni. Single-cell analysis of glycopeptide resistance gene expression in teicoplanin-resistant mutants of VanB Enterococcus f->aecalis. Mol Microbiol 1999; 32: 17-28.
• 4. Betlejewska K, Hryniewicz W. Nowe antybiotyki w leczeniu zakażeń wywołanych przez wielooporne szczepy ziarenkowców Gram-dodatnich. Nowa Med. 1999; 9: 35-39.
• 5. Bradley SJ, Wilson ALT, Allen MC i inni. The control hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999; 43: 261-66.
• 6. Dever LL, China C, Eng RH K i inni. Vancomycin-resistant Enterococcus faecium in a Veterans Affairs Medical Centre: association with antibiotic usage. Am J Infect Control 1998; 26: 40-46.
• 7. Hayden MK, Trenholme J, Schultz E, Sahm DF. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis 1993; 167: 1224-27.
• 8. Hryniewicz W, Szczypa K, Bronk A i inni. First report of vancomycin-resistant Enterococcus faecium isolated in Poland. Clin Microbiol Infect 1999; 5: 503-5.
• 9. Ieven M, Vercauteren P, Dcscheemaeker F i inni. Comparison of direct plating and broth enrichment culture for the detection of intestinal colonization by the glycopeptide-resistant Enterococci among hospitalized patients. J Clin Microbiol 1999; 37: 1436-40.
• 10. Jones RN, Pfaller MA, Envin ME, Bech ML. Antimicrobial activity of linezolid tested against 7599 recent clinical isolates from over 50 medical center laboratories. Presented at the Program and abstract of the 39,h Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 26-29, 1999.
• 11. Kawalec M, Gniadkowski M, Kędzierska J i inni. Selection of a teicoplanin-resistant Enterococcus faecium mutant during outbreak caused by vancomycin-resistant Enterococci with VanB phenotype. J Clin Microbiol 2001; 39: 325&-67.
• 12. Kawalec M, Gniadkowski M, Zaleska T i inni. Outbreak of vancomycin-resistant Enterococcus faecium of the phenotype VanB in a hospital in Warsaw, Poland: probable transmission of the resistance determinants into a endemic vancomycin-susceptible strain. J Clin Microbiol 2001; 39: 1781-87.
• 13. Kawalec M, Zaręba T. Patogeneza zakażeń enterokokowych. Nowa Med. 1997; 4: 26-30.
• 14. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997; 39: 145-151.
• 15. Łękowska-Kochaniak AE. Enterokoki (paciorkowce kałowe) - probiotyki czy patogeny? Post Mikrobiol 2000; 4: 341-61.
• 16. Murray BE. Vancomycin-resistant enterococcal infection. N Eng J Med. 2000; 342; 710-21.
• 17. Szczypa K, Hryniewicz W. Linezolid - nowe możliwości terapeutyczne. Nowa Klinika 2001; 8: 929-32.
• 18. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1989; 33: 1588-91.
• 19. Vancomycin resistant enterococci in hospitals in the United Kingdom (ed.): CDR Wkly 1995; 5: 281-84.
• 20.Van der Auwera P, Pensart N, Korten V i inni. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996; 173: 1129-36.
• 21. Wells Cl, Juni BA, Cameron SB i inni. Stool carriage, clinical isolation and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995; 21: 45-50.
• 22. Wieczyńska J, Kamińska W, Dzierżanowska D. Enterokoki - patogeny XXI wieku. Post Mikrobiol 2001; 40: 257-78.